ArticleJACC. Advances2026
Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is frequently preceded by carpal tunnel syndrome (CTS). The value of age- and biopsy-guided screening during CTS surgery for early detection of ATTR-CM remains uncertain.
objectivesWe aimed to determine the proportion of amyloid deposition in tenosynovial biopsies, the proportion of ATTR-CM among biopsy-positive patients, and to compare disease severity between screening-detected and clinically diagnosed ATTR-CM patients.
methodsThis prospective, multicenter cohort study enrolled men ≥65 and women ≥75 years undergoing surgery for idiopathic CTS and analyzed tenosynovial biopsies for amyloid deposition. Patients with amyloid-positive biopsies underwent cardiac workup, including echocardiography, bone scintigraphy, biomarker testing, and genetic testing to confirm ATTR-CM. A control cohort of contemporary clinically diagnosed wildtype ATTR-CM patients was included for comparison.
resultsIn total, 109 CTS patients were included (median age 79 years [IQR: 75-82]). Tenosynovial amyloid deposition was detected in 61/109 patients (56.0%; 95% CI: 46.1-65.5), of whom 52/61 patients completed cardiac evaluation. ATTR-CM was diagnosed in 9/52 patients (17.3%; 95% CI: 8.2-30.3; median age 83 years [IQR: 80-84]; male-to-female ratio 3.5:1; n = 7/2). Patients identified through screening had milder disease, 8/9 (89%) were in the National Amyloidosis Centre stage I compared to 26/47 (55%) among clinically diagnosed patients.
conclusionsSystematic age- and biopsy-guided screening during CTS surgery identified a high proportion of carpal amyloid deposition. Among amyloid-positive CTS patients, 1 in 6 was diagnosed with early-stage ATTR-CM. This approach demonstrated a higher yield in identifying ATTR-CM with mild disease burden and may serve as a tool for earlier diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.